• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Iteos Therapeutics Inc (NQ: ITOS )

    17.48 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 17.48
    Bid (Size) 17.32 (1)
    Ask (Size) 18.25 (1)
    Prev. Close 17.48
    Today's Range 17.48 - 17.48
    52wk Range 8.200 - 18.75
    Shares Outstanding 35,763,742
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q2 2024
    ITOS stock results show that ITeos Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +50.82%
    +50.82%
    1 Month
    +1.57%
    +1.57%
    3 Month
    +2.34%
    +2.34%
    6 Month
    +62.00%
    +62.00%
    1 Year
    +42.23%
    +42.23%

    More News

    Read More
    iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Recap: ITeos Therapeutics Q4 Earnings
    Via Benzinga
    iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos Therapeutics Announces $120 Million Registered Direct Offering
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023
    Via InvestorPlace
    iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos to Participate in Upcoming Investor Conferences
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.